NYSE - Nasdaq Real Time Price USD

Fresenius Medical Care AG (FMS)

20.08

-0.13

(-0.64%)

As of 2:07 PM EDT. Market Open.

Fresenius Medical Care (ETR:FME) earnings and shareholder returns have been trending downwards for the last five years, but the stock soars 14% this past week

Fresenius Medical Care AG ( ETR:FME ) shareholders should be happy to see the share price up 15% in the last month. But...

Simply Wall St. 2 days ago

FMCQF

FMS
-0.64%
Comfort Systems USA and Boeing have been highlighted as Zacks Bull and Bear of the Day

Comfort Systems USA and Boeing are part of the Zacks Bull and Bear of the Day article.

Zacks 14 days ago

BA

FIX

BAX
3 Medical Device Stocks With Solid Dividend Yield: CAH & Others

Here we discuss three medical device stocks, Cardinal Health (CAH), Baxter International (BAX) and Fresenius Medical Care (FMS), with a solid five-year dividend growth history.

Zacks 15 days ago

CAH

BAX

FME.DE
Reasons to Retain Fresenius Medical (FMS) in Your Portfolio Now

Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.

Zacks 16 days ago

FME.DE

DVA
-0.00%
Fresenius Medical Care (ETR:FME) Is Increasing Its Dividend To €1.19

Fresenius Medical Care AG ( ETR:FME ) will increase its dividend from last year's comparable payment on the 22nd of May...

Simply Wall St. 20 days ago

FME.DE
Fresenius Medical (FMS) to Unveil Training on Augmented Reality

Fresenius Medical (FMS) is launching digital learning elements with hands-on training for Kidney Replacement Therapy leveraging Augmented Reality.

Zacks last month

FME.DE

JNJ
What Makes Fresenius Medical Care AG (FMS) a Potential Investment?

Ariel Investments, an investment management company, released its “Ariel Global Fund” fourth-quarter 2023 investor letter. A copy of the same can be downloaded here. In the fourth quarter, the Ariel Global fund returned +8.40% gross of fees (+8.18% net of fees), compared to the MSCI ACWI Index’s +11.03%, and the MSCI ACWI Value Index’s +9.17% gains. […]

Insider Monkey last month

FME.DE
Fresenius Medical Care publishes 2023 joint Annual Report and Sustainability Report: Shaping the Future of Kidney Care

Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, today published its joint 2023 Annual Report and Non-financial Group Report, available digitally on the corporate website. Titled "Shaping the Future of Kidney Care," the report provides detailed information about Fresenius Medical Care's economic, social and environmental performance in 2023.

PR Newswire last month

FMCQF

FMS
-0.64%
Fresenius Medical Care launches "Augmented Reality" for training on Kidney Replacement Therapy device

Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, launches a new "Augmented Reality" (AR) application to make learning easier for nursing staff in Kidney Replacement Therapy in Intensive Care Units. The AR glasses, in combination with digital learning modules, allow nursing staff to learn how to use acute dialysis machines on site within the intensive care wards. The glasses stream visual and acoustic recordings as users inte

PR Newswire last month

FMCQF

FMS
-0.64%
Fresenius Medical (FMS) Divests Assets to Optimize Portfolio

Fresenius Medical's (FMS) latest asset divestments reflect a milestone in its portfolio optimization program and are likely to improve profitability.

Zacks last month

FME.DE

ZBH

CAH
Fresenius Medical Care (ETR:FME) Will Pay A Larger Dividend Than Last Year At €1.19

Fresenius Medical Care AG's ( ETR:FME ) dividend will be increasing from last year's payment of the same period to...

Simply Wall St. last month

FME.DE
Health Care Roundup: Market Talk

Read about Green Thumb Industries, Bayer, Fresenius Medical Care and more in the latest Market Talks covering the Health Care sector.

The Wall Street Journal last month

FMCQF

FMS
-0.64%
CNVVF
Why Dialysis Stocks Are up Today

Investors’ focus on the potential for Ozempic to disrupt various industries was on full display Tuesday. The industry in question this time: dialysis. Shares of companies providing dialysis services to kidney-disease patients, including Fresenius, DaVita and Outset Medical, were all up—Fresenius by some 11%—after drugmaker Novo Nordisk released [new details from a study of Ozempic](https://www.

The Wall Street Journal last month

FMCQF

FMS
-0.64%
OM
Fresenius Medical Care Achieves Next Milestone in Portfolio Optimization Program, Announcing Sale of Dialysis Clinics in Brazil, Colombia, Chile, Ecuador

Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, today announced the sale of its dialysis clinic networks in Brazil, Colombia, Chile and Ecuador to DaVita Inc. for a total transaction price of USD 300 million. Subject to regulatory approvals in Brazil, Colombia and Ecuador, the transactions represent another milestone in Fresenius Medical Care's portfolio optimization program, with each expected to close throughout 2024.

PR Newswire last month

FMCQF

FMS
-0.64%
Dialysis providers gain as investors focus on cardiac benefits after Ozempic's latest data

Shares of dialysis services providers jumped between 3% and 12% on Tuesday as latest data from Novo Nordisk's hugely popular diabetes drug Ozempic indicated a less-than-expected effect in chronic kidney disease patients. Investors, concerned after the interim data in October, are betting that most of the benefits of GLP-1 drugs such as Ozempic are related to cardiac events "rather than a game-changing extension in kidney disease progression, which the market has been worried about", said Morningstar analyst Julie Utterback. The potential for GLP-1 drugs such as Ozempic and Wegovy to treat health problems beyond diabetes and obesity has also hit shares in bariatric surgery providers, food firms and glucose-monitoring device makers.

Reuters last month

NVO

FME.DE
Fresenius Medical Care AG (ETR:FME) Just Released Its Full-Year Results And Analysts Are Updating Their Estimates

Shareholders might have noticed that Fresenius Medical Care AG ( ETR:FME ) filed its full-year result this time last...

Simply Wall St. 2 months ago

FME.DE
A Look At The Fair Value Of Fresenius Medical Care AG (ETR:FME)

Key Insights The projected fair value for Fresenius Medical Care is €34.47 based on Dividend Discount Model Fresenius...

Simply Wall St. 2 months ago

FME.DE
Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Q4 2023 Earnings Call Transcript

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Q4 2023 Earnings Call Transcript February 20, 2024 Fresenius Medical Care AG & Co. KGaA beats earnings expectations. Reported EPS is $0.44, expectations were $0.36. Fresenius Medical Care AG & Co. KGaA isn’t one of the 30 most popular stocks among hedge funds at the end of […]

Insider Monkey 2 months ago

FME.DE
Fresenius Swings to Net Loss After Fresenius Medical Care Deconsolidation

Fresenius reported an above-forecast 13% rise in underlying profit for the fourth quarter and forecast further growth in earnings and sales this year, and an improved cost-savings target for 2025.

The Wall Street Journal 2 months ago

FMCQF

FMS
-0.64%
Fresenius Medical Care delivers on commitments in a year of fundamental transformation

Helen Giza, Chief Executive Officer of Fresenius Medical Care, said: "In 2023, we delivered on our commitments while we fundamentally transformed Fresenius Medical Care. Exceeding our upgraded financial outlook for the full year was the very successful finish to an extraordinary year. We implemented the new global operating model, progressed on our operational turnaround ambitions, changed our legal form and advanced on the Portfolio Optimization Program through key divestments. Thanks to the co

PR Newswire 2 months ago

FMCQF

FMS
-0.64%

Performance Overview

Return	FMS	DAX PERFORMANCE-INDEX
YTD	-3.60%	+8.41%
1-Year	-10.99%	+14.42%
3-Year	-45.32%	+18.86%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Fresenius Medical Care AG (FMS)

Fresenius Medical Care (ETR:FME) earnings and shareholder returns have been trending downwards for the last five years, but the stock soars 14% this past week

Comfort Systems USA and Boeing have been highlighted as Zacks Bull and Bear of the Day

3 Medical Device Stocks With Solid Dividend Yield: CAH & Others

Reasons to Retain Fresenius Medical (FMS) in Your Portfolio Now

Fresenius Medical Care (ETR:FME) Is Increasing Its Dividend To €1.19

Fresenius Medical (FMS) to Unveil Training on Augmented Reality

What Makes Fresenius Medical Care AG (FMS) a Potential Investment?

Fresenius Medical Care publishes 2023 joint Annual Report and Sustainability Report: Shaping the Future of Kidney Care

Fresenius Medical Care launches "Augmented Reality" for training on Kidney Replacement Therapy device

Fresenius Medical (FMS) Divests Assets to Optimize Portfolio

Fresenius Medical Care (ETR:FME) Will Pay A Larger Dividend Than Last Year At €1.19

Health Care Roundup: Market Talk

Why Dialysis Stocks Are up Today

Fresenius Medical Care Achieves Next Milestone in Portfolio Optimization Program, Announcing Sale of Dialysis Clinics in Brazil, Colombia, Chile, Ecuador

Dialysis providers gain as investors focus on cardiac benefits after Ozempic's latest data

Fresenius Medical Care AG (ETR:FME) Just Released Its Full-Year Results And Analysts Are Updating Their Estimates

A Look At The Fair Value Of Fresenius Medical Care AG (ETR:FME)

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Q4 2023 Earnings Call Transcript

Fresenius Swings to Net Loss After Fresenius Medical Care Deconsolidation

Fresenius Medical Care delivers on commitments in a year of fundamental transformation

Performance Overview